摘要
EARCO登记处包含来自15个国家的100 000名AATD患者的信息。北欧和南欧国家的人口统计学特征和疾病特征没有显著差异。https://bit.ly/3EdGGcC
提取
α -1抗胰蛋白酶缺乏症(AATD)的特点是血清α -1抗胰蛋白酶(AAT)水平低,易导致肺气肿和肝脏疾病[1]。这种缺陷被认为是一种罕见的疾病,在西欧国家,其患病率为1 / 2400至1 / 6000。由于其低患病率,需要大量的观察性前瞻性登记来收集有关受影响个体的临床特征和预后的信息。
致谢
作者在此感谢参与本研究的患者和EARCO研究人员(如下所列)。我们要感谢Elise Heuvelin(瑞士洛桑欧洲呼吸学会)对EARCO管理188bet官网地址工作的支持,以及Gemma Vilagut和Christina Founti(西班牙巴塞罗那Bioclever公司)对EARCO数据监测工作的支持。我们还感谢Eduardo Loeb(西班牙巴塞罗那)参与了数据库的开发和数据的监测工作。
EARCO研究人员名单:george - christian Funk(奥地利);Wim Janssens, Silvia p
脚注
利益冲突:M. Miravitlles获得了来自阿斯利康、勃林格英格翰、Chiesi、Cipla、美纳里尼、Kamada、武田、赞邦、CSL Behring、Specialty Therapeutics、杨森、Grifols和诺华的演讲费,来自阿斯利康、Atriva Therapeutics、勃林格英格翰、Chiesi、葛兰素史克、CSL Behring、Inhibrx、Ferrer、Menarini、Mereo Biopharma、Spin Therapeutics、ONO Pharma、palobbiofarma SL、武田、诺华、诺和诺德、赛诺菲、赞邦和Grifols的咨询费,以及来自Grifols的研究资助。点特纳已获得阿斯利康、葛兰素史克、勃林格殷格翰、奇耶西、CSL Behring、武田、Vertex和Grifols生物治疗公司的资助或演讲费。他从Chiesi, CSL Behring, Grifols和Resmed获得演讲费,从CSL Behring和Grifols获得咨询费。J.L. López-Campos在过去的3年里,因在以下公司(按字母顺序排列)授课、提供科学建议、参与临床研究或撰写出版物而获得荣誉:阿斯利康、勃林格殷格翰、Chiesi、CSL Behring、Esteve、Ferrer、Gebro、葛兰素史克、Grifols、美纳里尼、诺华、罗维和梯瓦。J.L. Rodríguez-Hermosa已经收到了Zambon, Bial, Gebro Pharma, GlaxoSmithKline, Chiesi, Boehringer Ingelheim, CSL Behring和Grifols的演讲费。J.M. Hernández-Pérez获得了Grifols, CSL Behring, Astra-Zeneca, GSK, Bial实验室,Teva实验室的演讲费,参加Grifols, CSL Behring的会议的支持,以及CSL Behring的咨询费。F. Casas-Maldonado收到了来自阿斯利康、毕尔、勃林格殷格翰、Chiesi、Gebro Pharma、葛兰素史克、Laboratorios Esteve、Laboratorios Ferrer、Menarini、诺华、Rovi、TEVA、VERTEX、赞邦、CSL Behring和Grifols的演讲费,以及来自阿斯利康、Chiesi、葛兰素史克、CSL Behring和Grifols的咨询费。Barrecheguren先生从Grifols、Menarini、CSL Behring、GSK、Boehringer Ingelheim收取演讲费,并从GSK、Novartis、CSL Behring和Boehringer Ingelheim收取咨询费。 A. Bustamante has received speaker fees from Boehringer Ingelheim, AstraZeneca, GSK, Novartis and Ferrer, and funding for traveling or attending meetings from CSL Behring, AstraZeneca and Chiesi. C. González has received speaker fees from, Menarini, GSK, Novartis, Boehringer Ingelheim and Chiesi. C. Rodríguez-García has received speaker fees from GSK, AstraZeneca, Grifols, Chiesi, Ferrer, Menarini and Boehringer Ingelheim, expert testimony for Chiesi, support for attending meetings from FAES. C. Esquinas has received speaker fees from CSL Behring. C.F. Clarenbach received advisory fees from Roche, Novartis, Boehringer, GSK, Astra Zeneca, Sanofi, Vifor, OM Pharma, CSL Behring, Grifols, Daiichi Sankyo and MSD. C. Guimaraes reports support for the present manuscript from CSL Behring. C. Martinez-González reports lecture honoraria from Boehringer Ingelheim, Zambon; travel support from Roche; leadership role with SEPAR; outside the submitted work. A. Hecimovic reports lecture honoraria from Boehringer Ingelheim, Roche, MSD, Providens, CSL Behring; travel support from Boehringer Ingelheim, Roche; advisory board participation from Boehringer Ingelheim; outside the submitted work. W. Janssens reports grants from AstraZeneca and Chiesi Pharmaceuticals; consulting fees from AstraZeneca and Griphols; lecture honoraria from Chiesi, AZ, GSK; 3 KUL patents on pulmonary function tests; roles as Board Member – past president BERS, chair of Flemish Society for Tuberculosis and Tobacco Prevention; shareholder and co-founder of ArtiQ (AI spinoff company of KU Leuven); outside the submitted work. B. Lara reports travel support from ERS, supporting the present work. J. Stolk reports grants from CSL Behring, Kamada Ltd; outside the submitted work. The remaining authors report no conflicts of interest.
支持声明:国际EARCO登记处由Grifols、CSL Behring、Kamada、pH Pharma和武田向欧洲呼吸学会(ERS)提供的无限制赠款资助。188bet官网地址本文的资助信息已存入交叉基金注册处.
- 收到了2022年8月9日。
- 接受2023年2月10日。
- 版权所有©作者2023。获取转载权限请联系权限在}{ersnet.org